Lilly’s Breast Cancer Drug Combination Succeeds Key Study


Eli Lilly and Co’s combination of its experimental breast cancer drug and another widely used treatment slowed disease progression in patients who relapsed or did not benefit enough when treated with the anti-estrogen therapy.

“In August, an independent data monitoring committee recommended the late-stage study continue without modification, even though interim evaluation suggested the combination treatment was not delaying cancer progression.

“Lilly’s drug, abemaciclib, is part of the same new class of breast cancer treatments as Pfizer Inc’s Ibrance, and Novartis AG’s newly approved Kisqali.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.